ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wilson, C.
Right arrow Articles by Wilson, R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilson, C.
Right arrow Articles by Wilson, R
Eur Respir J 1997; 10: 1754-1760
Copyright © ERS Journals Ltd 1997

Original Articles

Effect of sputum bacteriology on the quality of life of patients with bronchiectasis

CB Wilson, PW Jones, CJ O'Leary, DM Hansell, PJ Cole, and R Wilson

Bronchiectatic patients have impaired health-related quality of life (QoL) and are prone to chronic lower respiratory tract infections. We have investigated whether impaired QoL is related to sputum bacteriology. Eighty seven patients with non-cystic fibrosis (non-CF) bronchiectasis, in a stable phase of their illness, completed three QoL measures, underwent a computed tomography (CT) scan and lung function tests, and provided a fresh sputum sample for microscopy and culture. The QoL of patients colonized by Pseudomonas aeruginosa (Pa group) was significantly worse than all other patients grouped together (non-Pa group), and specifically those infected by Haemophilus influenzae (Hi group) or who had no bacterial growth (NG group) (p<0.05), but not those infected by other bacterial species (O group). The Pa group had worse lung function, but no significant differences were found between the groups for forced expiratory volume in one second (FEV1) and peak expiratory flow rate. The Pa group had significantly worse bronchiectasis scores than the O, NG and non-Pa groups, but not the Hi group. There were no significant differences between the groups with respect to the number of infective exacerbations in the last year, but the Pa group had significantly more hospital admissions. Patients infected by P. aeruginosa for more than 3 yrs had significantly worse FEV1 (p<0.03) and bronchiectasis scores (p<0.05) than those infected with P. aeruginosa for less time, but not significantly worse QoL. We conclude that, overall, patients infected with P. aeruginosa have worse quality of life, and that P. aeruginosa is associated with a greater extent of disease and worse lung function. Although patients infected with H. influenzae had extensive bronchiectasis their quality of life was better than the P. aeruginosa infected group.


This article has been cited by other articles:


Home page
 Eur Respir JHome page
B. Ryall, J. C. Davies, R. Wilson, A. Shoemark, and H. D. Williams
Pseudomonas aeruginosa, cyanide accumulation and lung function in CF and non-CF bronchiectasis patients
Eur. Respir. J., September 1, 2008; 32(3): 740 - 747.
[Abstract] [Full Text] [PDF]

Home page
 Chronic Respiratory DiseaseHome page
J. Courtney, M. Kelly, A Watt, L Garske, J Bradley, M Ennis, and J. Elborn
Quality of life and inflammation in exacerbations of bronchiectasis
Chronic Respiratory Disease, August 1, 2008; 5(3): 161 - 168.
[Abstract] [PDF]

Home page
 ThoraxHome page
A B Chang and D Bilton
Exacerbations in cystic fibrosis: 4 {middle dot} Non-cystic fibrosis bronchiectasis
Thorax, March 1, 2008; 63(3): 269 - 276.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
G. Davies, A. U. Wells, S. Doffman, S. Watanabe, and R. Wilson
The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis
Eur. Respir. J., November 1, 2006; 28(5): 974 - 979.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. Bilton, N. Henig, B. Morrissey, and M. Gotfried
Addition of Inhaled Tobramycin to Ciprofloxacin for Acute Exacerbations of Pseudomonas aeruginosa Infection in Adult Bronchiectasis.
Chest, November 1, 2006; 130(5): 1503 - 1510.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. D. Macia, N. Borrell, M. Segura, C. Gomez, J. L. Perez, and A. Oliver
Efficacy and Potential for Resistance Selection of Antipseudomonal Treatments in a Mouse Model of Lung Infection by Hypermutable Pseudomonas aeruginosa
Antimicrob. Agents Chemother., March 1, 2006; 50(3): 975 - 983.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. J. Rosen
Chronic Cough Due to Bronchiectasis: ACCP Evidence-Based Clinical Practice Guidelines
Chest, January 1, 2006; 129(1_suppl): 122S - 131S.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. D. Macia, D. Blanquer, B. Togores, J. Sauleda, J. L. Perez, and A. Oliver
Hypermutation Is a Key Factor in Development of Multiple-Antimicrobial Resistance in Pseudomonas aeruginosa Strains Causing Chronic Lung Infections
Antimicrob. Agents Chemother., August 1, 2005; 49(8): 3382 - 3386.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
A. M. Li, S. Sonnappa, C. Lex, E. Wong, A. Zacharasiewicz, A. Bush, and A. Jaffe
Non-CF bronchiectasis: does knowing the aetiology lead to changes in management?
Eur. Respir. J., July 1, 2005; 26(1): 8 - 14.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
P. Scheinberg, E. Shore, and on behalf of the PC-TNDS-008 Study Group
A Pilot Study of the Safety and Efficacy of Tobramycin Solution for Inhalation in Patients With Severe Bronchiectasis
Chest, April 1, 2005; 127(4): 1420 - 1426.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M E. Drobnic, P. Sune, J B. Montoro, A. Ferrer, and R. Orriols
Inhaled Tobramycin in Non-Cystic Fibrosis Patients with Bronchiectasis and Chronic Bronchial Infection with Pseudomonas aeruginosa
Ann. Pharmacother., January 1, 2005; 39(1): 39 - 44.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
S. L. Chan, M. M. Chan-Yeung, G. C. Ooi, C. L. Lam, T. F. Cheung, W. K. Lam, and K. W. Tsang
Validation of the Hong Kong Chinese Version of the St. George Respiratory Questionnaire in Patients With Bronchiectasis
Chest, December 1, 2002; 122(6): 2030 - 2037.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M. Ferrer, C. Villasante, J. Alonso, V. Sobradillo, R. Gabriel, G. Vilagut, J.F. Masa, J.L. Viejo, C.A. Jimenez-Ruiz, and M. Miravitlles
Interpretation of quality of life scores from the St George's Respiratory Questionnaire
Eur. Respir. J., March 1, 2002; 19(3): 405 - 413.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
E Caballero, M-E Drobnic, M-T Perez, J-M Manresa, A Ferrer, and R Orriols
Anti-Pseudomonas aeruginosa antibody detection in patients with bronchiectasis without cystic fibrosis
Thorax, September 1, 2001; 56(9): 669 - 674.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
L. A. Couch
Treatment With Tobramycin Solution for Inhalation in Bronchiectasis Patients With Pseudomonas aeruginosa
Chest, September 1, 2001; 120(3_suppl): 114S - 117S.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
A. F. BARKER, L. COUCH, S. B. FIEL, M. H. GOTFRIED, J. ILOWITE, K. C. MEYER, A. O'DONNELL, S. A. SAHN, L. J. SMITH, J. O. STEWART, et al.
Tobramycin Solution for Inhalation Reduces Sputum Pseudomonas aeruginosa Density in Bronchiectasis
Am. J. Respir. Crit. Care Med., August 1, 2000; 162(2): 481 - 485.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
R. Wilson and R. B Dowling
Pseudomonas aeruginosa and other related species
Thorax, March 1, 1998; 53(3): 213 - 219.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the European Respiratory Society.